The pan-class I PI3K inhibitor, buparlisib, in combination with anti-PD-1 therapy, significantly inhibited tumour growth in the PyMT mammary tumour murine model compared to buparlisib or anti-PD-1 monotherapy alone [167]. Here, PIK3CA is linked to breast cancer.